2300
HR 3590 EAS/PP
ment, manufacturing, review, approval, and
1
safety surveillance of a medical product;
2
and
3
``(C) provide such additional information as
4
the Director of NIH may require.
5
``(3) A
WARDS
.--
6
``(A) T
HE CURES ACCELERATION PARTNER
-
7
SHIP AWARDS
.--
8
``(i) I
NITIAL
AWARD
AMOUNT
.--Each
9
award under this subparagraph shall be not
10
more than $15,000,000 per project for the
11
first fiscal year for which the project is
12
funded, which shall be payable in one pay-
13
ment.
14
``(ii) F
UNDING IN SUBSEQUENT FISCAL
15
YEARS
.--An eligible entity receiving an
16
award under clause (i) may apply for addi-
17
tional funding for such project by submit-
18
ting to the Director of NIH the information
19
required under subparagraphs (B) and (C)
20
of paragraph (2). The Director may fund a
21
project of such eligible entity in an amount
22
not to exceed $15,000,000 for a fiscal year
23
subsequent to the initial award under clause
24
(i).
25